1.           Introduction

1.1         Study Scope

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        North America Monoclonal Antibodies (mAbs) Market – By Source

1.3.2        North America Monoclonal Antibodies (mAbs) Market – By Production Method

1.3.3        North America Monoclonal Antibodies (mAbs) Market – By Indication

1.3.4        North America Monoclonal Antibodies (mAbs) Market – By Application

1.3.5        North America Monoclonal Antibodies (mAbs) Market – By End-User

1.3.6        North America Monoclonal Antibodies (mAbs) Market – By Geography

2.           Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Monoclonal Antibodies (mAbs) Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        North America PEST Analysis

4.3         Experts Opinion

5.           Monoclonal Antibodies (mAbs) Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Rising Prevalence of Cancer and Other Chronic Diseases

5.1.2        mABs Uptake Proves to be Effective During Pandemic Outbreak

5.2         Market Restraints

5.2.1        Low Awareness, Accessibility, and High Cost

5.3         Market Opportunities

5.3.1        Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity

5.4         Future Trends

5.4.1        Strategic Research Collaborations

5.5         Impact Analysis

6.           Monoclonal Antibodies (mAbs) Market– North America Analysis

6.1         North America Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis

7.           North America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028– by Source

7.1         Overview

7.2         North America Monoclonal Antibodies (mAbs) Market, By Source, 2020 & 2028 (%)

7.3         Murine

7.3.1        Overview

7.3.2        Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.4         Chimeric

7.4.1        Overview

7.4.2        Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.5         Humanized

7.5.1        Overview

7.5.2        Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.6         Human

7.6.1        Overview

7.6.2        Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

8.           Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Production Method

8.1         Overview

8.2         North America Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)

8.3         In-Vivo

8.3.1        Overview

8.3.2        In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

8.4         In-Vitro

8.4.1        Overview

8.4.2        In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.           Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Indication

9.1         Overview

9.2         North America Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)

9.3         Cancer

9.3.1        Overview

9.3.2        Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.4         Autoimmune Diseases

9.4.1        Overview

9.4.2        Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.5         Inflammatory Diseases

9.5.1        Overview

9.5.2        Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.6         Infectious Diseases

9.6.1        Overview

9.6.2        Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.7         Microbial Diseases

9.7.1        Overview

9.7.2        Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.8         Others

9.8.1        Overview

9.8.2        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Application

10.1      Overview

10.2      North America Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)

10.3      Diagnostic Applications

10.3.1     Overview

10.3.2     Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.4      Therapeutic Applications

10.4.1     Overview

10.4.2     Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.5      Research Applications

10.5.1     Overview

10.5.2     Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – End-User

11.1      Overview

11.2      North America Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)

11.3      Hospitals

11.3.1     Overview

11.3.2     Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.4      Research Institutes

11.4.1     Overview

11.4.2     Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.5      Others

11.5.1     Overview

11.5.2     Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

12.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 – Geographical Analysis

12.1      North America: Monoclonal Antibodies (mAbs) Market

12.1.1     Overview

12.1.2     North America: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.3     North America: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)

12.1.4     North America: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)

12.1.5     North America: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)

12.1.6     North America: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)

12.1.7     North America: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)

12.1.8     North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)

12.1.8.1       US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.1.1       Overview

12.1.8.1.2       US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.1.3       US: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)

12.1.8.1.4       US: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)

12.1.8.1.5       US: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)

12.1.8.1.6       US: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)

12.1.8.1.7       US: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)

12.1.8.2       Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2.1       Overview

12.1.8.2.2       Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2.3       Canada: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)

12.1.8.2.4       Canada: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)

12.1.8.2.5       Canada: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)

12.1.8.2.6       Canada: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)

12.1.8.2.7       Canada: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)

12.1.8.3       Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3.1       Overview

12.1.8.3.2       Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3.3       Mexico: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (US$ Million)

12.1.8.3.4       Mexico: Monoclonal Antibodies (mAbs) Market, by Production, 2019–2028 (US$ Million)

12.1.8.3.5       Mexico: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (US$ Million)

12.1.8.3.6       Mexico: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (US$ Million)

12.1.8.3.7       Mexico: Monoclonal Antibodies (mAbs) Market, by End-User, 2019–2028 (US$ Million)

13.        Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market

13.1      North America: Impact Assessment of COVID-19 Pandemic

14.        Monoclonal Antibodies (mAbs) Market–Industry Landscape

14.1      Overview

14.2      Growth Strategies Done by the Companies in the Market, (%)

14.3      Organic Developments

14.3.1     Overview

14.4      Inorganic Developments

14.4.1     Overview

15.        Company Profiles

15.1      Novartis AG

15.1.1     Key Facts

15.1.2     Business Description

15.1.3     Products and Services

15.1.4     Financial Overview

15.1.5     SWOT Analysis

15.1.6     Key Developments

15.2      Pfizer Inc.

15.2.1     Key Facts

15.2.2     Business Description

15.2.3     Products and Services

15.2.4     Financial Overview

15.2.5     SWOT Analysis

15.2.6     Key Developments

15.3      GlaxoSmithKline plc.

15.3.1     Key Facts

15.3.2     Business Description

15.3.3     Products and Services

15.3.4     Financial Overview

15.3.5     SWOT Analysis

15.3.6     Key Developments

15.4      Amgen Inc.

15.4.1     Key Facts

15.4.2     Business Description

15.4.3     Products and Services

15.4.4     Financial Overview

15.4.5     SWOT Analysis

15.4.6     Key Developments

15.5      DAIICHI SANKYO COMPANY LIMITED

15.5.1     Key Facts

15.5.2     Business Description

15.5.3     Products and Services

15.5.4     Financial Overview

15.5.5     SWOT Analysis

15.5.6     Key Developments

15.6      F. HOFFMANN-LA ROCHE LTD.

15.6.1     Key Facts

15.6.2     Business Description

15.6.3     Products and Services

15.6.4     Financial Overview

15.6.5     SWOT Analysis

15.6.6     Key Developments

15.7      AstraZeneca

15.7.1     Key Facts

15.7.2     Business Description

15.7.3     Products and Services

15.7.4     Financial Overview

15.7.5     SWOT Analysis

15.7.6     Key Developments

15.8      Eli Lilly and Company.

15.8.1     Key Facts

15.8.2     Business Description

15.8.3     Products and Services

15.8.4     Financial Overview

15.8.5     SWOT Analysis

15.8.6     Key Developments

15.9      Bayer AG

15.9.1     Key Facts

15.9.2     Business Description

15.9.3     Products and Services

15.9.4     Financial Overview

15.9.5     SWOT Analysis

15.9.6     Key Developments

15.10   Bristol-Myers Squibb Company

15.10.1  Key Facts

15.10.2  Business Description

15.10.3  Products and Services

15.10.4  Financial Overview

15.10.5  SWOT Analysis

15.10.6  Key Developments

16.        Appendix

16.1      About The Insight Partners

16.2      Glossary of Terms

LIST OF TABLES

Table 1.             North America Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)

Table 2.             North America Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028  (USD Million)

Table 3.             North America Monoclonal Antibodies (mAbs) Market, by Indication– Revenue and Forecast to 2028 (US$ Million)

Table 4.             North America Monoclonal Antibodies (mAbs) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 5.             North America Monoclonal Antibodies (mAbs) Market, by End-User– Revenue and Forecast to 2028 (US$ Million)

Table 6.             US Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)

Table 7.             US Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)

Table 8.             US Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 9.             US Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 10.          US Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Canada: Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)

Table 12.          Canada Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)

Table 13.          Canada Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Canada Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 15.          Canada Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 16.          Mexico: Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Mexico Monoclonal Antibodies (mAbs) Market, by Production– Revenue and Forecast to 2028 (US$ Million)

Table 18.          Mexico Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 19.          Mexico Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 20.          Mexico Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 21.          Organic Developments Done by Companies

Table 22.          Inorganic Developments Done by Companies

Table 23.          Glossary of Terms

LIST OF FIGURES

Figure 1.           Monoclonal Antibodies (mAbs) Market Segmentation

Figure 2.           North America Monoclonal Antibodies (mAbs) Market Overview

Figure 3.           Human Segment Held Largest Share of Source Segment in Monoclonal Antibodies (mAbs) Market

Figure 4.           US is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           North America Monoclonal Antibodies (mAbs) Market, Industry Landscape

Figure 6.           North America: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           Impact Analysis of Drivers and Restraints Pertaining to Monoclonal Antibodies (mAbs) Market

Figure 9.           North America Monoclonal Antibodies (mAbs) Market – By Geography Forecast and Analysis – 2021 - 2028

Figure 10.        North America Monoclonal Antibodies (mAbs) Market, by Source, 2020 & 2028 (%)

Figure 11.        Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 12.        Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 13.        Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 14.        Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 15.        North America Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)

Figure 16.        In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 17.        In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 18.        North America Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)

Figure 19.        Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 20.        Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 21.        Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 22.        Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 23.        Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 24.        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 25.        North America Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)

Figure 26.        Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 27.        Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 28.        Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 29.        North America Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)

Figure 30.        Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 31.        Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 32.        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 33.        North America: Monoclonal Antibodies (mAbs) Market, by Key Country – Revenue (2021) (US$ Million)

Figure 34.        North America Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

Figure 35.        North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)

Figure 36.        US: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37.        Canada: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38.        Mexico: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39.        Impact of COVID-19 Pandemic in North American Country Markets

Figure 40.        Growth Strategies Done by the Companies in the Market, (%)